Cargando…
Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
BACKGROUND: Treatment of severe diffuse congenital hyperinsulinism (CHI) without sufficient response to diazoxide is complicated by the lack of approved drugs. Therefore, patients are often hospitalized long-term or have to undergo pancreatic surgery if episodes of severe hypoglycaemia cannot be pre...
Autores principales: | Corda, Heike, Kummer, Sebastian, Welters, Alena, Teig, Norbert, Klee, Dirk, Mayatepek, Ertan, Meissner, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455078/ https://www.ncbi.nlm.nih.gov/pubmed/28576129 http://dx.doi.org/10.1186/s13023-017-0653-x |
Ejemplares similares
-
Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers
por: Welters, Alena, et al.
Publicado: (2015) -
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008) -
Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016) -
Risk Factors for Adverse Neurodevelopment in Transient or Persistent Congenital Hyperinsulinism
por: Roeper, Marcia, et al.
Publicado: (2020) -
Anxiety, depression, and quality of life in parents of children with congenital hyperinsulinism
por: Roeper, Marcia, et al.
Publicado: (2022)